IMR
data caveat$594M—
Imricor Medical Systems
Cardiac
Vision-MR ablation system for cardiac catheter ablation under real-time MRI guidance
Data HealthTrials2 of 2 active · stale enrollment
No cash data on fileFigures from ASX filings · not financial advice
[ VITALS ]
Cash on Hand
—
Runway
—Market Cap
$594M
Burn Rate
—
Shares Outstanding
353M
Pipeline Assets
2
Latest Insightprice-sensitive announcements & broker notes
Price-sensitiveCapital Raise3 May 2026
Imricor Completes Successful A$60 Million Capital Raise
$60.0MPlacement·at$1.85·32.4M shares
Lead: Morgans Corporate Limited, Canaccord Genuity (Australia) Limited, Taylor Collison Limited
3M Price
IMR.ASX$1.680-13.0% 3M
Low $1.680High $2.110
Pipeline Assets (2)
Vision-MR Deflectable SheathMRI-guided cardiac catheter navigation
ApprovedVision-MR Ablation CatheterCardiac arrhythmia (MRI-guided ablation)
ApprovedDiscovery
Preclinical
Ph 1
Ph 1/2
Ph 2
Ph 2/3
Ph 3
NDA
Capital Raises & Buybacks
12mo dilution 9.2%12mo $60M1 raise
Current shares outstanding: 353M
Placement
2026-05-04placement
$60.0M
Other ticker dataInsider activity, holders, grants, publications
expand ›
Insider activity, holders, grants, publications
Director Transactions
5 transactionsLast 90dNo Activity
Buys0
Sells0
PERFORMANCE RIGHTSAldo Dentiopen_in_new
2026-05-14
11d after · Proposed issue of securities - IMR
Catalysts (4)· 2 upcoming · 2 past
SpeculativeremoveMed1 Dec 2026
SpeculativeremoveMed31 Dec 2026
expand_more2 past catalysts
Track RecordDelivery Consistency Index
expand ›
Delivery Consistency Index
Historical delivery and spending consistency. Data is limited for recently added companies.
Delivery Consistency Index
Delivery
–Insufficient data
2/3 data points needed
Timeline adherence · phase-adjusted tolerance · recency-weighted · min 3 catalysts
Capital discipline
–Insufficient data
0/2 data points needed
Burn rate stability · stage-adjusted thresholds · runway trend · R&D focus
Hit 2 of 2 guided dates· rolling 2yr(limited sample)· of 4 tracked
Completed catalysts
✓Proposed issue of securities - IMR
On time
✓Imricor Completes Successful A$60 Million Capital Raise
On time
Outcome quality (positive/negative readouts) reflects the science, not execution — shown above but excluded from the score.
These metrics reflect historical operational data only. They are not predictive of future performance, do not constitute investment advice, and should not be used as the basis for any investment decision.
Clinical Trials(2)
2 activeClinicalTrials.gov ↗
NARecruitingEnrollment stale · 720d
RF Ablation
Atrial Flutter Ablation in the iCMR
Atrial Flutter Typical
18 Years+
Primary endpoint Primary Efficacy Endpoint: Bi-directional block confirmation
ENROL91
no manual snapshots — enter via record_enrollment.py
NARecruitingEnrollment stale · 426d
Vision-MR Ablation Catheter 2.0
VT Ablation in the iCMR
Ventricular Tachycardia
18 Years+
Primary endpoint Primary Efficacy Endpoint
ENROL64
no manual snapshots — enter via record_enrollment.py